Embraer sees lot of opportunities in India; in talks with IndiGo, Air India, ET Infra
4 min read
Embraer sees lot of opportunities in India; in talks with IndiGo, Air India
Besides, the company is in talks with IndiGo and Air India to explore the possibility of selling its E-2 aircraft, which can have up to 146 seats.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
an hour ago
- News18
ITR Filing 2025: 6 Key Reporting Changes In ITR -2 Form That Taxpayers Must Know
Last Updated: ITR Filing FY2025-26: The tax department linked the changes in the utilities forms for FY2024-25 as a major reason for the delay in the release of these utilities. ITR Filing FY2025-26: The income tax department has released the Excel-based utilities for ITR forms 2 and 3 after a delay, allowing eligible taxpayers to complete their tax duties before the deadline. The utilities for forms 1 and 4 were already released a month and a half ago. With this, all major utilities from forms 1, 2, 3 and 4 are now working on the income tax portal. The income tax department has already extended the deadline for tax filing for FY2024-25 (assessment year FY2025-26) to September 15, 2025 from July 31, 2025. The tax department linked the changes in the utilities forms for FY2024-25 as a major reason for the delay in the release of these utilities, leading to the extension of the deadline for this filing year. There are some major changes in ITR-2 form, which is applicable for those who earn a salary or have non-business or professional income as well as those with crypto, capital gains and other types of income. Let's see what are these six changes in the reporting process for the ITR-2 form. CA Suresh Surana explains to the Economic Times the six prominent changes in reporting mechanism in ITR-2 excel utility. view comments Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
The Hindu
2 hours ago
- The Hindu
Air India finds no issues with locking mechanism of fuel control switch in B787 planes: Official
Air India on Wednesday (July 16, 2025) completed the inspection of the locking mechanism of fuel control switches in its Boeing 787 planes and did not find any issues, according to an airline official. On Monday, aviation watchdog DGCA directed airlines to inspect the fuel switch locking system in their Boeing 787 and 737 planes against the backdrop of AAIB's preliminary report stating that fuel switches were cut off before the Air India plane crash that killed 260 people last month. "Over the weekend, our Engineering team initiated precautionary inspections on the locking mechanism of Fuel Control Switch (FCS) on all our Boeing 787 aircraft. The inspections have been completed and no issues were found," the official said, quoting an internal message sent to Air India pilots. The official also said that all the Boeing 787-8 aircraft have undergone Throttle Control Module (TCM) replacement as per the Boeing maintenance schedule. FCS is part of this module. FCS regulate the flow of fuel into the aircraft engines. In its preliminary report on the Boeing 787-8 crash released on Saturday, the Aircraft Accident Investigation Bureau (AAIB) said the fuel supply to both engines of the plane was cut off within a gap of one second, causing confusion in the cockpit soon after take off. A 15-page preliminary investigation report into the Air India plane crash revealed fuel-control switches of the two engines moved from the "run" to the "cutoff" position, within the space of one second, leading to immediate loss of altitude. "In the cockpit voice recording, one of the pilots is heard asking the other why did he cut off? The other pilot responded that he did not do so," the report said. AAIB, which mentioned about FAA's SAIB in the report, did not suggest any recommended action. The airline has also asked pilots to remain vigilant and report any defect in the technical log, as per the existing reporting process, the official added.
Time of India
2 hours ago
- Time of India
Glenmark Pharmaceuticals targets 70% branded portfolio by 2030, boosts focus on novel drugs
Glenmark Pharmaceuticals is pivoting to a sharper, innovation-driven company over the next 4-5 years with focus on its novel drug portfolio and strengthening its branded business, managing director Glenn Saldanha said. Glenmark 3.0 will look at bulking up its branded portfolio to 70% by 2030 from the current 60% with focus on three of its key therapeutic areas where the company is putting all its muscle to scale, he said at an investor's day meet in Mumbai. "2030 and onwards we see ourselves as a leading global innovation-driven company with leadership in three therapeutic areas that is dermatology, respiratory and oncology ," said Saldanha. "We are a $1.6 billion organisation and last year, 60% of our revenue came from branded products." Explore courses from Top Institutes in Select a Course Category Data Science Operations Management Cybersecurity Product Management Digital Marketing Public Policy Degree Technology PGDM Others MBA Management healthcare Finance Artificial Intelligence Healthcare Design Thinking others Project Management CXO Data Science Data Analytics Leadership MCA Skills you'll gain: Duration: 10 Months IIM Kozhikode CERT-IIMK DABS India Starts on undefined Get Details Skills you'll gain: Duration: 30 Weeks IIM Kozhikode SEPO - IIMK-AI for Senior Executives India Starts on undefined Get Details Skills you'll gain: Duration: 11 Months E&ICT Academy, Indian Institute of Technology Guwahati CERT-IITG Postgraduate Cert in AI and ML India Starts on undefined Get Details Skills you'll gain: Duration: 10 Months E&ICT Academy, Indian Institute of Technology Guwahati CERT-IITG Prof Cert in DS & BA with GenAI India Starts on undefined Get Details Skills you'll gain: Duration: 11 Months IIT Madras CERT-IITM Advanced Cert Prog in AI and ML India Starts on undefined Get Details The roadmap for the next 4-5 years includes increasing contribution from high-growth EU and EM markets, growing the US generic business via respiratory, injectables product launches and growing a robust pipeline of innovative multi-specifics ( novel drugs to treat cancers) through Ichnos Glenmark Innovation (IGI). IGI last week entered a landmark pact with US-based AbbVie to develop and commercialise its innovative drug ISB 2001 used for the treatment of multiple myeloma, a rare form of blood cancer. It will get an upfront payment of $700 million (about Rs 6,000 crore) from AbbVie, in addition to potential milestone-linked payments of $1.2 billion. "We are looking at leveraging the platform and expanding on that further to continue to add more value," he said. Live Events Company executives said in territories where Glenmark gets the commercial rights of ISB 2001 the market opportunity will be $5 billion. "3.0 is all about moving up the value chain to become an innovation-led company with a large commercial footprint and transforming into something global," said Saldanha, seeking to differentiate the organisation from its domestic peers. "The second part of it is to create long-term sustainable value for all our stakeholders and ensure great return ratios." "The next 10 years are going to be about trying to create something transformational, focus on moving up the value chain, launch branded products and doing this in a fiscally disciplined manner where we have good margins and returns," he said.
